ICOS and cancer: For the most common cancer types in the current study, ICOS and ICOSL high were co-expressed in 2.0% (colorectal) to 14.6% (pancreatic), whereas ICOSL high was co-expressed with ICOS not high in 29.1% (pancreatic) to 46.4% (colorectal) of patients.